SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that it has entered into a clinical collaboration with Sarah Cannon Research Institute (SCRI),
Expands patent protection for liquid biopsy platform SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today announced receipt of a U.S.
Clinical utility and clinical validation of CTCs and ctDNA to analyze cancer biomarkers ALK, ROS1 and EGFR demonstrated SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the LD Micro
Announces Increased Revenues and Strong Year-over-Year Growth in Test Volume Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , May 12, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
SAN DIEGO , May 4, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced that the Company will issue its financial results for the first
SAN DIEGO, March 24, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that it has entered into a clinical collaboration with
Adds to Portfolio of Blood-Based 'Liquid Biopsies' With EGFR Mutation Identification to Assist Physicians With Treatment Decisions for Lung Cancer Patients
SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended
